Urge Urinary Incontinence
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasSolifenacin
PfizerFesoterodine
Human BioSciencesBotulinum toxin A
Antares Therapeuticsoxybutynin
Clinical Trials (4)
Total enrollment: 1,658 patients across 4 trials
Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Start: Mar 2012Est. completion: Jun 2017138 patients
Phase 4Completed
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Start: Jan 2009Est. completion: May 2011645 patients
Phase 4Completed
Anticholinergic vs. Botox Comparison Study
Start: Mar 2010Est. completion: May 2012249 patients
Phase 3Completed
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Start: Mar 2009Est. completion: Nov 2010626 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.